These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 22351689)

  • 21. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
    Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
    Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
    Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
    Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
    Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
    Hong SP; Ahn SK
    Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.
    Martin MJ; Hayward R; Viros A; Marais R
    Cancer Discov; 2012 Apr; 2(4):344-55. PubMed ID: 22576211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
    Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
    Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
    Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
    Clin Cancer Res; 2011 Oct; 17(20):6482-9. PubMed ID: 21831957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
    Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
    Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.
    Conrad WH; Swift RD; Biechele TL; Kulikauskas RM; Moon RT; Chien AJ
    Cell Cycle; 2012 Oct; 11(20):3724-30. PubMed ID: 22895053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of sorafenib in metastatic melanoma with tissue correlates.
    Ott PA; Hamilton A; Min C; Safarzadeh-Amiri S; Goldberg L; Yoon J; Yee H; Buckley M; Christos PJ; Wright JJ; Polsky D; Osman I; Liebes L; Pavlick AC
    PLoS One; 2010 Dec; 5(12):e15588. PubMed ID: 21206909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
    J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
    Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
    Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.